Biotechnology

Noul's Hydrogel Stamping is the potential core technology necessary for precise cancer diagnosis, study confirmed

* The method shows highly efficient and simple on immunostaining  * Research Paper by Biotech Start up Noul, Harvard Medical School, and Massachusetts General Hospital Published on American Chemical Society Applied Materials and Interfaces. YONGIN, South Korea, July 27, 2022 /PRNewswire/ -- A ...

2022-07-27 20:00 2025

Samsung Biologics Reports Second Quarter 2022 Financial Results

* Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed onApril 20, 2022 * Achieved record-high semi-annual revenue exceeding KRW 1 trillion * Recorded Q2'22 revenue of KRW 503.7 billion for the company's CDMO business * Recorded ...

2022-07-27 14:43 1926

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

SINGAPORE, July 26, 2022 /PRNewswire/ --  Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus (MPXV), for research use only (RUO). The ViroKey® MPXV PCR Test allows for the prompt, in vitro detection of MPXV DNA from human skin lesion specimens. It is co...

2022-07-26 22:09 2408

Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...

2022-07-26 20:30 1690

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

* Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 inAustralia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines fo...

2022-07-26 20:00 1897

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre

* All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported * The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all H...

2022-07-26 17:04 2044

Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022 /PRNewswire/ --Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, andTanner Ph...

2022-07-25 21:59 2310

Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA

HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...

2022-07-25 18:47 1963

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

* Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins * Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial * A$4.1 million R&D Tax Incentive Scheme refund * Cash balance on 30 June 2022 of A$34.8M MELBOURN...

2022-07-22 19:25 1633

AI-based Cancer Solution Pioneer Lunit Makes Market Debut

SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker "A32813". Lunit's initial public offering of 1,215,800 shares of its common stock was priced a...

2022-07-21 21:00 1641

ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities

SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjec...

2022-07-21 08:00 1597

Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...

2022-07-19 20:00 1541

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data fro...

2022-07-18 20:00 1766

OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002

SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...

2022-07-18 20:00 1532

Samsung Biologics to purchase land for its second Bio Campus

* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...

2022-07-18 19:00 1587

Lunit to be Listed on KOSDAQ next week

* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed on the KOSDAQ market on July 21, 2022 SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- Lunit, a global provider of AI-based cancer solutions, announced that it priced its initial public offering (I...

2022-07-14 21:00 2047

Bridge Biotherapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of BBT-176 at the World Conference of Lung Cancer

* The abstract suggests that BBT-176 has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients * Further exploration of the drug efficacy and safety profiles at RP2D is planned * The abstract is now available on the IASLC 2022 WCLC website SEON...

2022-07-13 06:30 1911

KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER

SYDNEY, July 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of four distinguished clinicians and scientists with expertise in...

2022-07-12 20:15 2333

iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates

* Shows potent and rapid antibacterial activity against clinical isolates in Europe and Korea both * CDL200,  a novel endolysin pipeline for the treatment of Clostridioides difficile Infection (CDI) * The world's first endolysin in capsule formulation to be administered orally BOSTON and SEO...

2022-07-12 10:06 1590

'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report

* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. * Details new social contribution activities that strives to support the health of its local communities. * Requires commitment to the Supplier Cod...

2022-07-11 19:00 1964
1 ... 72737475767778 ... 127